Zeneca Limited

John Frederick Hennam

David Huw Davies

Peter R Marsham

David Charles Blakey

Anthony Michael Slater

Laurent Francois Andre Hennequin

Francis Thomas Boyle

Robert I Dowell

David William Heaton

Laurent Francois Hennequin

Brian Robert Rabin

Antonio Tarragona-Fiol

Hendrikus Johannes Eggelte

Christopher John Taylorson

Antibody Directed Enzyme Prodrug Therapy (ADEPT) systems for use in cancer based on mutated carboxypeptidase B (CPB) enzymes. Enzyme conjugates for ADEPT are substantially non-immunogenic in humans comprising a targeting moiety (for example an antibody) capable of binding with a tumor associated antigen, the targeting moiety being linked to a mutated form of a CPB enzyme capable of converting a prodrug into an antineoplastic drug wherein the prodrug is not significantly convertible into antineoplastic drug in humans by natural unmutated enzyme. A preferred enzyme mutant is human pancreatic CPB comprising a Lys or Arg residue at position 253. Suitable mustard prodrugs are disclosed in the specification.

Chemical compounds

Growing community of inventors

Macclesfield, United Kingdom

John Frederick Hennam